title: Cyclosporin A in combination with HAART in primary HIV-1 infection.
abstract: HAART is the cornerstone of HIV therapy, and has significantly reduced morbidity and mortality associated with HIV disease. The institution of HAART during the primary HIV-1 infection has a more profound influence on the ultimate pattern and rate of disease progression than therapy commenced later on. However, it also well demonstrated that HAART alone is not able to eradicate the virus, unless over a life-long period of time. There is therefore the need to develop alternative strategies aimed at modulating the immune responses in order to achieve the long-term control of HIV even once HAART is discontinued. Among immunomodulant agents, cyclosporin A in combination with HAART might play a role in the treatment of people with primary HIV-1 infection.
authors.affiliation: Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland. Paolo.Rizzardi@chuv.hospvd.ch
authors.forename: G P
authors.initials: GP
authors.lastname: Rizzardi
authors.forename: M
authors.initials: M
authors.lastname: Vaccarezza
authors.forename: B
authors.initials: B
authors.lastname: Capiluppi
authors.forename: G
authors.initials: G
authors.lastname: Tambussi
authors.forename: A
authors.initials: A
authors.lastname: Lazzarin
authors.forename: G
authors.initials: G
authors.lastname: Pantaleo
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D016516:CD4-CD8 Ratio; D016572:Cyclosporine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D015497:HIV-1; D006801:Humans
chemical_list: D019380:Anti-HIV Agents; D016572:Cyclosporine